Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
BAY-3827 is an inhibitor of AMP-activated protein kinase (AMPK; IC50 = 1.4 nM at 10 µM ATP).1 It is selective for AMPK over Aurora A kinase, FMS-related tyrosine kinase 3 (FLT3), and c-Met (IC50s = 1,324, 124, and 788 nM, respectively), p90 ribosomal S6 kinase 2 (RSK2), RSK3, RSK4, p90 ribosomal S6 kinase 1 (MSK1), and MST3 (IC50s = 52, 36, 24, 43, and 94 nM, respectively), and a panel of 331 kinases at 10 µM but does inhibit RSK1 (IC50 = 9 nM). BAY-3827 selectively inhibits the proliferation of androgen-dependent LNCaP, VCaP, and 22Rv1 prostate cancer cells (IC50s = 0.28, 1.71, and 5.55 µM, respectively) over androgen receptor-negative C4-2B, PC3, and DU145 prostate cancer cells (IC50s = >10 µM for all).
WARNING This product is not for human or veterinary use.
1. The potent AMPK inhibitor BAY-